AlphaQuest’s RxSight RXST Stock Holding History

AlphaQuest’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,727	Closed	-$372K	–	1685
2025 Q4	$372K	Sell	35,727 -2,360	-6%	-$23.7K	0.02%	1054
2025 Q3	$342K	Buy	38,087 +29,479	+342%	+$259K	0.02%	1073
2025 Q2	$112K	Buy	8,608 +165	+2%	+$2.48K	0.01%	1388
2025 Q1	$213K	Buy	8,443 +3,357	+66%	+$99.8K	0.02%	957
2024 Q4	$175K	Buy	5,086 +2,017	+66%	+$91K	0.02%	908
2024 Q3	$152K	Buy	3,069 +2,381	+346%	+$122K	0.01%	1176
2024 Q2	$41.4K	Buy	+688	New	+$39.3K	0.01%	1104

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

AlphaQuest's RXST Position: Q1 2026 in Review

AlphaQuest sold out of RxSight (RXST) in Q1 2026, closing a stake of 35,727 shares — an estimated $372K sold.

AlphaQuest first reported a position in RXST in Q2 2024 and held it in 7 quarters. The position peaked at $372K in Q4 2025. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

AlphaQuest reported no remaining RxSight position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 35,727 RxSight shares in Q1 2026, an estimated $372K.
AlphaQuest first reported a position in RxSight in Q2 2024 and held it in 7 quarters.
AlphaQuest's RxSight position peaked at $372K in Q4 2025.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.